Company intelligence / Profile preview

EPOK Therapeutics

Toronto, Ontario, Canadaepoktherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company’s lead programs are in preclinical and GMP cell-line development. EPRA-0322, a mono-specific antibody EPO receptor agonist, is being developed for anemia in CKD and cancer patients. KLOT-1123 targets FGF23 for phosphate wasting disorders such as hypophosphatemic rickets and CKD. No clinical results have been published yet.[1][4][5]

Therapeutic areas: EndocrinologyNephrology
Modalities: Monoclonal antibodiesAntibody-drug conjugates
Industry: Biotech

Drug pipeline

3 assets

EPRA-0322

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on EPOK Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPOK Therapeutics.

Explore the full profile